| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2006;37:2957.)
© 2006 American Heart Association, Inc.
Original Contributions |
From Institute for Clinical Research and Health Policy Studies and Department of Medicine (D.M.K., H.P.S., R.R.), Tufts-New England Medical Center, Tufts University School of Medicine, Boston, Mass; Boehringer Ingelheim (E.B.), Ingelheim, Germany; Department of Neurology (W.H.), University of Heidelberg, Heidelberg, Germany.
Correspondence to David M. Kent, MD, MS, Institute for Clinical Research and Health Policy Studies, Tufts-New England Medical Center, 750 Washington St, #63, Boston, MA, 02111. E-mail Dkent1{at}tufts-nemc.org
Background and Purpose Many patients with ischemic stroke eligible for recombinant tissue plasminogen activator (rt-PA) are not treated in part because of the risks and benefits perceived by treating physicians. Therefore, we aimed to develop a Stroke-Thrombolytic Predictive Instrument (TPI) to aid physicians considering thrombolysis for stroke.
Methods Using data from 5 major randomized clinical trials (n=2184) testing rt-PA in the 0- to 6-hour window, we developed logistic regression equations using clinical variables as potential predictors of a good outcome (modified Rankin Scale score
1) and of a catastrophic outcome (modified Rankin Scale score
5), with and without rt-PA. The models were internally validated using bootstrap re-sampling.
Results To predict good outcome, in addition to rt-PA treatment, 7 variables significantly affected prognosis and/or the treatment-effect of rt-PA: age, diabetes, stroke severity, sex, previous stroke, systolic blood pressure, and time from symptom onset. To predict catastrophic outcome, only age, stroke severity, and serum glucose were significant; rt-PA treatment was not. For patients treated within 3 hours, the median predicted probability of a good outcome with rt-PA was 42.9% (interquartile range [IQR]=18.6% to 64.7%) versus 25.3% (IQR=9.8% to 46.2%) without rt-PA; the median predicted absolute benefit was 12.5% (IQR=5.1% to 21.0%). The median probability for a catastrophic outcome, with or without, rt-PA was 15.2% (IQR=8.0% to 31.2%). The area under the receiver-operator characteristic curve was 0.788 for the model predicting good outcome and 0.775 for the model predicting bad outcome.
Conclusions The Stroke-TPI predicts good and bad functional outcomes with and without thrombolysis. Incorporated into a usable tool, it may assist in decision-making.
Key Words: acute care acute Rx acute stroke clinical decision support emergency medicine predictive models thrombolysis thrombolytic Rx
Related Article:
Stroke 2006 37: 2865-2866.
This article has been cited by other articles:
![]() |
M Uyttenboogaart, R E Stewart, P C Vroomen, G-J Luijckx, and J De Keyser Utility of the stroke-thrombolytic predictive instrument J. Neurol. Neurosurg. Psychiatry, September 1, 2008; 79(9): 1079 - 1081. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yong and M. Kaste Association of Characteristics of Blood Pressure Profiles and Stroke Outcomes in the ECASS-II Trial Stroke, February 1, 2008; 39(2): 366 - 372. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Kent, H. P. Selker, R. Ruthazer, E. Bluhmki, and W. Hacke Can Multivariable Risk-Benefit Profiling Be Used to Select Treatment-Favorable Patients for Thrombolysis in Stroke in the 3- to 6-Hour Time Window? Stroke, December 1, 2006; 37(12): 2963 - 2969. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Demaerschalk The Stroke-Thrombolytic Predictive Instrument Provides Valid Quantitative Estimates of Outcome Probabilities and Aids Clinical Decision-Making Stroke, December 1, 2006; 37(12): 2865 - 2866. [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |